Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial
{{output}}
The Superior Yield of the New Strategy of Enoxaparin, Revascularization, and GlYcoprotein IIb/IIIa inhibitors (SYNERGY) was a randomized, open-label, multicenter clinical trial comparing 2 anticoagulant drugs on the basis of time-to-event endpoints. In contras... ...
